Anaphylaxis

Our top 5 headlines include 5 key FDA decisions, including the first approval for stroke in 3 decades, an expanded indication for pediatric anaphylaxis, and more!

The FDA approval for epinephrine nasal spray 1 mg is indicated for type 1 allergic reactions in children 15 to 30 kg and 4 years or older.

Castells discusses improvements in symptoms and quality of life scores for patients with indolent systemic mastocytosis across >2 years of the PIONEER trial.

A study at AAAAI 2025 found that monitoring transepidermal water loss during oral food challenges reduced anaphylaxis rates and epinephrine use in children.

A 46-member expert panel created a consensus anaphylaxis definition, overview, and clinical tool to aid clinicians in recognition and management across settings.

In this quiz, we test your knowledge of anaphylaxis risk assessment, prevention strategies, and best practices for enhancing preparedness.

A Kingston study finds a 15.94% biphasic anaphylaxis rate, with recurrence at 19 hours, prompting concerns about extending emergency department observation.

A study found higher daily temperatures increased anaphylaxis risk, except for cases related to medical procedures, highlighting heat's role in allergic reactions.

In this quiz, we test your knowledge of evidence-based management strategies, recommended epinephrine doses, and evolving guidance on patient follow-up and discharge planning for anaphylaxis.

A study found 1 in 7 children with anaphylaxis experience biphasic reactions after epinephrine, with no recurrences after 4 hours, highlighting corticosteroid impact.

Children with urticaria or angioedema face greater risks of adverse events after COVID-19 vaccination, but most tolerate subsequent doses with proper management.

Data from the CAFETERIA trial provide insight into exposure vs avoidance strategies for high-threshold peanut allergy.

An analysis found anaphylaxis following non-COVID vaccines is rare, with greater rates for yellow fever and influenza vaccines.

Test your knowledge of the 2023 Anaphylaxis Update from the Joint Task Force on Practice Parameters, focusing on diagnoses and biomarkers!

Needle-free treatments, such as Neffy and FluMist, offer promising alternatives for children and adults with needle phobia, ensuring access to critical care.

The FDA affirmed the planned NDA content and format for Anaphylm expected in Q1 2025, without requiring additional adult clinical trials before submission.

These data were explored to identify risk, recommendations, and guidelines related to vaccine-related allergic reactions such as anaphylaxis.

In recent findings presented at ACAAI 2024, patients, caregivers, and even emergency medical professionals were shown to face issues with regard to treatment of anaphylaxis reactions.

The Parental Self-efficacy in Managing Anaphylaxis (PSEMA) questionnaire was shown to be effective in assessing self-efficacy of parents in managing their childrens’ conditions.

Aquestive Therapeutics plans to submit an NDA for Anaphylm in Q1 2025 based on topline results from the Oral Allergy Syndrome challenge study.

Early epinephrine intervention at home can potentially successfully treat anaphylaxis in children without further treatment in a hospital setting.

During situations in which those with severe allergies suffer from fatal anaphylaxis, adrenaline autoinjectors were shown in this study to have little effect on such reactions.

In the allergy news space, this Month in Review highlights some of the most significant stories covered by the editorial team.

The announcement follows July’s approval of the nasal spray, also known as neffy, for patients with Type 1 allergic reactions such as anaphylaxis.